Free Newsletter
Drugs discounted to boost compliance
Drugmakers have come up with all sorts of ways to get folks to take their drugs as directed: mailouts, e-mails, phone calls, even gadget giveaways. But still, people with chronic health problems fail to follow through. Now, a big insurer and several drugmakers are appealing to patients where it really counts: the pocketbook.
UnitedHealth Group is offering $20 discounts off monthly copays for certain asthma meds and antidepressants--provided patients stick to their regimens, the Wall Street Journal reports. The price break only works when members refill their scrips on time. Qualifying antidepressants include Eli Lilly's Cymbalta, and Wyeth's Effexor XR and Pristiq; asthma meds include GlaxoSmithKline's Advair and AstraZeneca's Symbicort. These branded drugs have $50 co-pays on some UnitedHealth plans, so a $20 discount would take the co-pay down to $30.
To make the program work, drugmakers had to play ball, considering the discounts in their rebate deals with UnitedHealth. The idea being, of course, that the price cut would not only encourage patients to keep refilling their scrips, but also to stick with the branded version of the drug rather than switching to a generic. No details on the financial terms, but they must be favorable enough; GlaxoSmithKline, for one, said that it's working other insurers on "this kind of innovative program."
- see the WSJ story
ALSO: More than 50 percent of adults under 45 who are prescribed a statin to treat high cholesterol aren't taking their meds as prescribed, according to a CVS Caremark study. Report
Related Articles:
Study: Lower prices don't harm innovation
Brits profit by exporting newly cheap drugs
Cash-poor patients cut back on meds
Branded meds suffer two times over
Americans prioritize medication prices
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: